{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:16:53Z","timestamp":1760217413284,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Intradetrusor injections of Botulinum toxin A\u2014currently onabotulinumtoxinA\u2014is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 \u00d7 1 mL injections in the detrusor; however, protocols remain variable and standardization is warranted. The effect of reducing the number of injection sites of Dysport\u00ae abobotulinumtoxinA (aboBoNTA) was assessed in the spinal cord-injured rat (SCI). Nineteen days post-spinalization, female rats received intradetrusor injections of saline or aboBoNTA 22.5 U distributed among four or eight sites. Two days after injection, continuous cystometry was performed in conscious rats. Efficacy of aboBoNTA 22.5 U was assessed versus aggregated saline groups on clinically-relevant parameters: maximal pressure, bladder capacity, compliance, voiding efficiency, as well as amplitude, frequency, and volume threshold for nonvoiding contractions (NVC). AboBoNTA 22.5 U significantly decreased maximal pressure, without affecting voiding efficiency. Injected in four sites, aboBoNTA significantly increased bladder capacity and compliance while only the latter when in eight sites. AboBoNTA significantly reduced NVC frequency and amplitude. This preclinical investigation showed similar inhibiting effects of aboBoNTA despite the number of sites reduction. Further studies are warranted to optimize dosing schemes to improve the risk-benefit ratio of BoNTA-based treatment modalities for NDO and further idiopathic overactive bladder.<\/jats:p>","DOI":"10.3390\/toxins7124896","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T10:47:37Z","timestamp":1450349257000},"page":"5462-5471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport\u00ae) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?"],"prefix":"10.3390","volume":"7","author":[{"given":"Am\u00e9lie","family":"Huynh Le Maux","sequence":"first","affiliation":[{"name":"Pelvipharm, 2 avenue de la source de la Bi\u00e8vre, B\u00e2timent Simone Veil, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, France"},{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2025-5249","authenticated-orcid":false,"given":"Bernadette","family":"Pignol","sequence":"additional","affiliation":[{"name":"IPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Behr-Roussel","sequence":"additional","affiliation":[{"name":"Pelvipharm, 2 avenue de la source de la Bi\u00e8vre, B\u00e2timent Simone Veil, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, France"},{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Blachon","sequence":"additional","affiliation":[{"name":"IPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Etienne","family":"Chabrier","sequence":"additional","affiliation":[{"name":"IPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Compagnie","sequence":"additional","affiliation":[{"name":"Pelvipharm, 2 avenue de la source de la Bi\u00e8vre, B\u00e2timent Simone Veil, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, France"},{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Picaut","sequence":"additional","affiliation":[{"name":"IPSEN Innovation, 5 avenue du Canada, Les Ulis 91140, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Bernab\u00e9","sequence":"additional","affiliation":[{"name":"Pelvipharm, 2 avenue de la source de la Bi\u00e8vre, B\u00e2timent Simone Veil, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux 78180, France"},{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"},{"name":"Assistance Publique-H\u00f4pitaux de Paris, Neuro-Uro-Andrology, Raymond Poincar\u00e9 Hospital, Department of Physical Medicine and Rehabilitation, Garches 92380, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Denys","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Formation et de Recherche des Sciences de la Sant\u00e9, Universit\u00e9 de Versailles-Saint-Quentin-en-Yvelines, Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale U1179, Montigny-le-Bretonneux 78180, France"},{"name":"Assistance Publique-H\u00f4pitaux de Paris, Neuro-Uro-Andrology, Raymond Poincar\u00e9 Hospital, Department of Physical Medicine and Rehabilitation, Garches 92380, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","article-title":"Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract","volume":"169","author":"Smith","year":"2003","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","article-title":"Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection","volume":"56","author":"Liu","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0361-9230(03)00114-X","article-title":"Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions","volume":"61","author":"Smith","year":"2003","journal-title":"Brain Res. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/nau.21068","article-title":"Central inhibitory effect of intravesically applied botulinum toxin A in chronic spinal cord injury","volume":"30","author":"Munoz","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/nau.21102","article-title":"Researching bladder afferents\u2014determining the effects of \u03b23-adrenergic receptor agonists and botulinum toxin type-A","volume":"30","author":"Kanai","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","article-title":"Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomised, placebo-controlled, double-blind study","volume":"41","author":"Ehren","year":"2007","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: A randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_17","first-page":"1289","article-title":"Success rate and patients' satisfaction following intradetrusor dysport injection in patients with detrusor overactivity: A comparative study of idiopathic and neurogenic types of detrusor overactivity","volume":"11","author":"Shakeri","year":"2014","journal-title":"Urol. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuint.2007.11.006","article-title":"Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury","volume":"52","author":"Smith","year":"2008","journal-title":"Neurochem. Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1097\/01.ju.0000180410.78774.b5","article-title":"The effects of botulinum-A toxin on bladder function and histology in spinal cord injured rats: Is there any difference between early and late application?","volume":"174","author":"Temeltas","year":"2005","journal-title":"J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2007.07.013","article-title":"Comparison of the effects of complete and incomplete spinal cord injury on lower urinary tract function as evaluated in unanesthetized rats","volume":"208","author":"Leung","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2012.01.051","article-title":"Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity","volume":"61","author":"Oger","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.expneurol.2004.02.014","article-title":"The role of capsaicin-sensitive afferent fibers in the lower urinary tract dysfunction induced by chronic spinal cord injury in rats","volume":"187","author":"Cheng","year":"2004","journal-title":"Exp. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","article-title":"Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: A case-control study","volume":"104","author":"Grosse","year":"2009","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2710.2007.00835.x","article-title":"Comparing two botulinum toxin type A formulations using manufacturers\u2019 product summaries","volume":"32","author":"Wenzel","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1179\/2045772313Y.0000000116","article-title":"Use of botulinum toxin in individuals with neurogenic detrusor overactivity: State of the art review","volume":"36","author":"Linsenmeyer","year":"2013","journal-title":"J. Spin. Cord Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","article-title":"Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: A systematic literature review","volume":"53","author":"Karsenty","year":"2008","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.ju.0000169481.42259.54","article-title":"Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity","volume":"174","author":"Apostolidis","year":"2005","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0022-5347(06)00258-8","article-title":"Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity","volume":"175","author":"Giannantoni","year":"2006","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2012.11.009","article-title":"Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity","volume":"68","author":"Giannantoni","year":"2013","journal-title":"Pharmacol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.juro.2012.07.001","article-title":"Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats","volume":"188","author":"Takahashi","year":"2012","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00345-008-0362-0","article-title":"A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging","volume":"27","author":"Mehnert","year":"2009","journal-title":"World J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","article-title":"Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action","volume":"61","author":"Coelho","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1569-9056(07)60885-9","article-title":"Botulinum toxin-A (BTA) in the treatmentof neurogenic detrusor overactivity incontinence (NDOI)d a prospective randomized study to compare 30 vs. 10 injection sites (abstract 890)","volume":"6","author":"Karsenty","year":"2007","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liao, C.H., Chen, S.F., and Kuo, H.C. (2015). Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourol. Urodyn.","DOI":"10.1002\/nau.22780"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/mds.25582","article-title":"Diffusion, spread, and migration of botulinum toxin","volume":"28","author":"Jankovic","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxicon.2011.05.012","article-title":"Characterization of diffusion and duration of action of a new botulinum toxin type A formulation","volume":"58","author":"Stone","year":"2011","journal-title":"Toxicon"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1381\/0960892055002275","article-title":"Effect on gastric emptying and weight reduction of botulinum toxin-A injection into the gastric antral layer: An experimental study in the obese rat model","volume":"15","author":"Coskun","year":"2005","journal-title":"Obes. Surg."},{"key":"ref_39","first-page":"522","article-title":"Botulinum-A toxin in the treatment of detrusor hyperreflexia","volume":"20","year":"2001","journal-title":"Neurourol. Urodyn."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.urology.2003.12.007","article-title":"Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents","volume":"63","author":"Kuo","year":"2004","journal-title":"Urology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","article-title":"Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: Comparison of two doses","volume":"58","author":"Grise","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.sc.3101736","article-title":"Adverse events after botulinum A toxin injection for neurogenic voiding disorders","volume":"43","author":"Wyndaele","year":"2005","journal-title":"Spin. Cord"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/7\/12\/4896\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:54:14Z","timestamp":1760216054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/7\/12\/4896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["toxins7124896"],"URL":"https:\/\/doi.org\/10.3390\/toxins7124896","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2015,12,17]]}}}